US › Healthcare

C4 Therapeutics Inc (CCCC)

US · Healthcare · Biotechnology

$3.61+3.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$6.2M
Revenue YoY
-15.0%
Net profit
$-25.1M
Profit YoY
+4.5%
EPS
$-0.20
EPS estimate
$-0.26
Net margin
-408.5%

EPS came in at -0.20 against a street estimate of -0.26 — a beat of 23.1%.

Key statistics

Market cap
$392.5M
Forward P/E
0.0
P/B
1.69
Book value
$2.25
EPS (TTM)
$-1.10
52-week high
$5.17
52-week low
$1.69
50-day MA
$3.90
200-day MA
$2.84
Beta
2.91

Analyst view

Analysts rate C4 Therapeutics Inc a buy (4 buy, 4 hold, 0 sell out of 8) with an average price target of $13.33.

Shareholding

Insiders
0.93%
Institutions
86.92%

Largest institutional holders

FundStake
Morgan Stanley - Brokerage Accounts8.21%
RA Capital Management, LLC7.24%
Bain Capital Life Sciences Investors, LLC6.49%
Lynx1 Capital Management, LP6.33%
Vanguard Group Inc3.96%
Vanguard Capital Management, LLC3.49%
Soleus Capital Management, L.P.3.44%
Wasatch Advisors LP3.19%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for C4 Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.